ALK and cancer: A group of isolated cancer patients with neuropathic pain showed a significant response to EGFR inhibitors [86,87], while a meta-analysis of ALK inhibitors intended to treat NSCLC revealed that a subgroup of patients experienced reduced musculoskeletal pain [88].